Vanda Pharmaceuticals (VNDA) Equity Ratio (2010 - 2026)

Vanda Pharmaceuticals has disclosed Equity Ratio across 17 years of filings, most recently posting 0.65 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.65, down 19.97% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.65 (down 19.97% YoY), and the FY2025 annual result was 0.67, down 18.46% from the prior year.
• Equity Ratio came in at 0.65 for Q1 2026 at Vanda Pharmaceuticals, down from 0.67 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.85 in Q3 2023 to a low of 0.65 in Q1 2026.
• The 5-year median for Equity Ratio is 0.83 (2022), against an average of 0.81.
• Across the five-year window, Equity Ratio increased 2.07% in 2023 and fell 19.97% in 2026, its largest moves.
• Vanda Pharmaceuticals' Equity Ratio stood at 0.83 in 2022, then rose by 1.1% to 0.84 in 2023, then fell by 2.34% to 0.82 in 2024, then dropped by 18.46% to 0.67 in 2025, then retreated by 3.22% to 0.65 in 2026.
• The last three Equity Ratio figures came in at 0.65 (Q1 2026), 0.67 (Q4 2025), and 0.78 (Q3 2025), per Business Quant data.